AU2008318778B2 - Targeting microRNAs for the treatment of liver cancer - Google Patents

Targeting microRNAs for the treatment of liver cancer Download PDF

Info

Publication number
AU2008318778B2
AU2008318778B2 AU2008318778A AU2008318778A AU2008318778B2 AU 2008318778 B2 AU2008318778 B2 AU 2008318778B2 AU 2008318778 A AU2008318778 A AU 2008318778A AU 2008318778 A AU2008318778 A AU 2008318778A AU 2008318778 B2 AU2008318778 B2 AU 2008318778B2
Authority
AU
Australia
Prior art keywords
moe
certain embodiments
modified oligonucleotide
nucleobase sequence
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008318778A
Other languages
English (en)
Other versions
AU2008318778A1 (en
Inventor
C. Frank Bennett
Ayelet Chajut
Christine Esau
Eric G. Marcusson
Noga Yerushalmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulus Therapeutics Inc
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of AU2008318778A1 publication Critical patent/AU2008318778A1/en
Assigned to Regulus Therapeutics Inc. reassignment Regulus Therapeutics Inc. Request for Assignment Assignors: Regulus Therapeutics Inc., ROSETTA GENOMICS LTD.
Application granted granted Critical
Publication of AU2008318778B2 publication Critical patent/AU2008318778B2/en
Priority to AU2014271307A priority Critical patent/AU2014271307A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008318778A 2007-10-29 2008-10-29 Targeting microRNAs for the treatment of liver cancer Active AU2008318778B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014271307A AU2014271307A1 (en) 2007-10-29 2014-12-04 Targeting microRNAs for the treatment of liver cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98323107P 2007-10-29 2007-10-29
US60/983,231 2007-10-29
PCT/US2008/081645 WO2009058907A2 (en) 2007-10-29 2008-10-29 Targeting micrornas for the treatment of liver cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014271307A Division AU2014271307A1 (en) 2007-10-29 2014-12-04 Targeting microRNAs for the treatment of liver cancer

Publications (2)

Publication Number Publication Date
AU2008318778A1 AU2008318778A1 (en) 2009-05-07
AU2008318778B2 true AU2008318778B2 (en) 2014-10-02

Family

ID=40524369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008318778A Active AU2008318778B2 (en) 2007-10-29 2008-10-29 Targeting microRNAs for the treatment of liver cancer

Country Status (8)

Country Link
US (6) US8211867B2 (https=)
EP (1) EP2217248B1 (https=)
JP (1) JP5535076B2 (https=)
CN (1) CN101980712B (https=)
AU (1) AU2008318778B2 (https=)
CA (1) CA2704043C (https=)
IL (1) IL205307A (https=)
WO (1) WO2009058907A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US8211867B2 (en) 2007-10-29 2012-07-03 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer
CA2716906A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011017456A2 (en) * 2009-08-04 2011-02-10 Northwestern University Localized delivery of nanoparticles for therapeutic and diagnostic applications
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US9334495B2 (en) * 2009-11-25 2016-05-10 Elitechgroup B.V. Minor groove binder (MGB)-oligonucleotide miRNA antagonists
WO2011076141A1 (en) * 2009-12-24 2011-06-30 Fudan University Diagnostic kits comprising microrna biomarkers and methods for diagnosis of hepatocellular cancer
CN101831427B (zh) * 2010-04-01 2012-07-18 清华大学深圳研究生院 一种预防肿瘤复发和抑制肿瘤生长的寡聚核酸及其应用
EP2576785A4 (en) * 2010-06-04 2014-12-24 Univ Texas METABOLIC CHANGE BY ME-378
CN103189511B (zh) * 2010-07-12 2016-10-12 国立大学法人鸟取大学 利用siRNA导入的新型hiPSC制作法
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
CN102140471B (zh) * 2011-01-10 2013-11-20 清华大学深圳研究生院 一种抑制肿瘤生长的寡聚核酸及其应用
CN102125696B (zh) * 2011-01-11 2013-06-12 清华大学深圳研究生院 抑制肿瘤生长及血管生成的寡聚核酸组合物及其应用
SG10201600836PA (en) 2011-02-03 2016-03-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
US8420617B2 (en) 2011-03-11 2013-04-16 Biocell Laboratories Multiantivirus compound, composition and method for treatment of virus diseases
CN102178959B (zh) * 2011-03-15 2013-10-23 清华大学深圳研究生院 抑制肺转移肿瘤生长的siRNA及其寡聚核酸组合与应用
WO2012145374A1 (en) * 2011-04-19 2012-10-26 Regulus Therapeutics Inc. TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
HUE031595T2 (en) * 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
EP2705157B1 (en) * 2011-05-06 2017-02-01 New England Biolabs, Inc. Ligation enhancement
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) * 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
EA030211B1 (ru) 2012-04-25 2018-07-31 Регьюлэс Терапьютикс Инк. Соединения на основе микрорнк и способы модулирования активности mir-21
JP2014027898A (ja) * 2012-07-31 2014-02-13 Yamaguchi Univ 肝細胞がん発症リスクの判定方法
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN108026528A (zh) * 2015-08-20 2018-05-11 比奥基内生物科学协会合作研究中心 治疗肝疾病和病症的方法和组合物
EP3446515B1 (en) 2016-04-20 2020-12-02 Convida Wireless, LLC System information provisioning
KR102153077B1 (ko) 2016-04-20 2020-09-07 콘비다 와이어리스, 엘엘씨 다운링크 동기화
JP6837492B2 (ja) 2016-04-20 2021-03-03 コンヴィーダ ワイヤレス， エルエルシー 新しい無線における物理チャネル
WO2017184865A1 (en) 2016-04-20 2017-10-26 Convida Wireless, Llc Configurable reference signals
EP3455985B1 (en) 2016-05-11 2022-03-09 Convida Wireless, LLC New radio downlink control channel
WO2017218847A1 (en) 2016-06-15 2017-12-21 Convida Wireless, Llc Grant-less operations
WO2017218849A1 (en) 2016-06-15 2017-12-21 Convida Wireless, Llc Network slice discovery and selection
JP2019518392A (ja) 2016-06-15 2019-06-27 コンヴィーダ ワイヤレス， エルエルシー 新しい無線のための許可不要アップリンク伝送
CN109565370B (zh) 2016-06-15 2021-06-15 康维达无线有限责任公司 用于新无线电的上传控制信令的装置
US10840982B2 (en) 2016-08-11 2020-11-17 Convidia Wireless, LLC Beamforming sweeping and training in a flexible frame structure for new radio
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN109891772B (zh) 2016-11-03 2022-10-04 康维达无线有限责任公司 Nr中的帧结构
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN112753265B (zh) 2018-09-27 2025-02-11 交互数字专利控股公司 新无线电的未经许可的频谱中的子频带操作
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
WO2023060237A1 (en) * 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Methods and compositions for treatment of polycystic kidney disease
WO2025104709A1 (en) * 2023-11-17 2025-05-22 Biorchestra Co., Ltd. Microrna-378a-3p antisense oligonucleotides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118806A2 (en) * 2004-05-28 2005-12-15 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
WO2006111512A1 (en) * 2005-04-19 2006-10-26 Basf Plant Science Gmbh Improved methods controlling gene expression
WO2007112753A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070884A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP4334165B2 (ja) 2001-07-13 2009-09-30 コニカミノルタホールディングス株式会社 静電潜像現像用トナーと画像形成方法及び画像形成装置
EP2447370B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
JP4369691B2 (ja) 2003-06-26 2009-11-25 株式会社Ｉｄｘ マイクロ波化学反応装置
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005014793A2 (en) * 2003-08-07 2005-02-17 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling
JP3959722B2 (ja) 2003-10-15 2007-08-15 住友金属工業株式会社 線材コイルの冷却装置
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
CN1800388A (zh) * 2005-01-07 2006-07-12 中国人民解放军军事医学科学院放射医学研究所 八种人源miRNA
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
JP2007073737A (ja) 2005-09-07 2007-03-22 Toyo Ink Mfg Co Ltd 複数の導電性回路層を有するプリント配線板並びにその製造方法
DE102005046385B4 (de) 2005-09-28 2012-03-22 Siemens Ag Verfahren und Vorrichtung zur Nachbearbeitung eines 3D-Bilddatensatzes, insbesondere für die virtuelle Kolonographie
JP2007097429A (ja) * 2005-09-30 2007-04-19 Mitsubishi Rayon Co Ltd ｎｏｎ−ｃｏｄｉｎｇＲＮＡの検出データ補正方法
JP4483757B2 (ja) 2005-09-30 2010-06-16 セイコーエプソン株式会社 有機ｅｌ装置及び光学装置
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
WO2007073737A1 (en) * 2005-12-29 2007-07-05 Exiqon A/S Detection of tissue origin of cancer
AU2007211082B2 (en) * 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
US20080312099A1 (en) * 2006-02-15 2008-12-18 University Of Louisville Research Foundation, Inc. Microarray, System, and Method for Detecting, Identifying, and Quantitating Micro-Rnas
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2041317A4 (en) * 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
US20080199961A1 (en) * 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
US8252538B2 (en) * 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
JP2009043353A (ja) 2007-08-09 2009-02-26 Pioneer Electronic Corp タイトル付与装置、タイトル付与方法、タイトル付与プログラム、および記録媒体
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US8211867B2 (en) 2007-10-29 2012-07-03 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118806A2 (en) * 2004-05-28 2005-12-15 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
WO2006111512A1 (en) * 2005-04-19 2006-10-26 Basf Plant Science Gmbh Improved methods controlling gene expression
WO2007112753A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides

Also Published As

Publication number Publication date
US20180127755A1 (en) 2018-05-10
US9150857B2 (en) 2015-10-06
US20140206854A1 (en) 2014-07-24
CN101980712B (zh) 2015-02-18
US9845470B2 (en) 2017-12-19
US10301627B2 (en) 2019-05-28
CA2704043C (en) 2018-09-18
US20160046941A1 (en) 2016-02-18
US20170137811A1 (en) 2017-05-18
WO2009058907A2 (en) 2009-05-07
EP2217248B1 (en) 2016-11-30
JP5535076B2 (ja) 2014-07-02
US9506062B2 (en) 2016-11-29
US20100267814A1 (en) 2010-10-21
US20120295962A1 (en) 2012-11-22
US8680067B2 (en) 2014-03-25
IL205307A0 (en) 2010-12-30
IL205307A (en) 2015-10-29
JP2011501962A (ja) 2011-01-20
US8211867B2 (en) 2012-07-03
EP2217248A2 (en) 2010-08-18
US20110251150A2 (en) 2011-10-13
WO2009058907A3 (en) 2009-12-17
AU2008318778A1 (en) 2009-05-07
CA2704043A1 (en) 2009-05-07
CN101980712A (zh) 2011-02-23

Similar Documents

Publication Publication Date Title
AU2008318778B2 (en) Targeting microRNAs for the treatment of liver cancer
AU2017219156B2 (en) MicroRNA compounds and methods for modulating miR-21 activity
EP2841579B1 (en) Microrna compounds and methods for modulating mir-21 activity
WO2011088309A1 (en) Microrna compositions and methods
AU2014271307A1 (en) Targeting microRNAs for the treatment of liver cancer
HK40065959A (en) Microrna compounds and methods for modulating mir-21 activity
HK1243130B (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585B (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585A (en) Microrna compounds and methods for modulating mir-21 activity
HK1207115B (en) Microrna compounds and methods for modulating mir-21 activity

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: REGULUS THERAPEUTICS INC.

Free format text: FORMER APPLICANT(S): ROSETTA GENOMICS LTD.; REGULUS THERAPEUTICS INC.

FGA Letters patent sealed or granted (standard patent)